Experts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its Phase 2 trial of lonigutamab in TED and prepares to initiate Phase 3 program in first quarter of 2025 LOS ANGELES, Oct. 16, 2024 (GLOBE NEWSWIRE) — ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the […]

TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company“) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer(TM), Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and artificial intelligence markets, has been named the winner of the “Best in Artificial Intelligence”

SAN MATEO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase (FASN) inhibitor, denifanstat, and preclinical data demonstrating atherosclerosis improvement with FASN inhibitor

Faster, smarter delivery robots will support Serve’s scaling across the U.S. Manufacturing cost halved, while advancing safety, autonomy, performance and speed New robots have entered manufacturing and are on track for deployment in 2025 SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) — Serve Robotics Inc. (“Serve”) (Nasdaq: SERV), a leading autonomous sidewalk delivery company, today

Hydreight reported record Topline(1) Revenue of $10.46M in the first 6 months of 2024. Q2, 2024 GAAP revenue was $4.10 million an increase of 52% compared to Q2, 2023. Q2, 2024 Adjusted EBITDA(1) was $218K compared to ($456K) in the comparative quarter. In partnership with two other companies, Hydreight launched Telemedicine and e-Commerce Solution that

Scilex Holding Company seeks to maximize the value of its stockholders, including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals (“Scilex Pharma”) in markets and on securities exchanges in or outside of the U.S., including Hong Kong. Scilex Holding Company management believes the potential value of Scilex Pharma may

SEATTLE, Oct. 16, 2024 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today is celebrating the first shipment and patient dosing from its second manufacturing facility for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals. Located

Megan Baldwin, PhD, MAICD, to retire from the Board and has chosen not to stand for re-election As Founder and Chief Innovation Officer, Dr. Baldwin will continue focusing on advancing Opthea’s innovation agenda MELBOURNE, Australia and PRINCETON, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company

All amounts expressed in US dollars TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) — Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) (“Barrick” or the “Company”) today reported preliminary Q3 production of 943 thousand ounces of gold and 48 thousand tonnes of copper, as well as preliminary Q3 sales of 967 thousand ounces of gold and 42 thousand tonnes of

Schaumburg, IL, Oct. 16, 2024 (GLOBE NEWSWIRE) — The American Society for Dermatologic Surgery Association (ASDSA) is pleased to announce the recipients of its annual Patient Safety Hero Award awarded at the ASDS / ASDSA Annual Meeting. This year’s award is being presented to members who have taken an active role in promoting and protecting